/PRNewswire/ After the successful launch of their Dermatology CRO, the fast-growing San Francisco healthcare company, Vial, has disclosed plans to launch an.
/PRNewswire/ After the successful launch of their Dermatology CRO, the fast-growing San Francisco healthcare company, Vial, has disclosed plans to launch an.
Bausch + Lomb Presents Data from First Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the American Society of Cataract and Refractive Surgery Annual Meeting - read this article along with other careers information, tips and advice on BioSpace
/PRNewswire/ Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), and Novaliq GmbH, a.
Bausch + Lomb, a unit of Bausch Health (BHC) , said a phase 3 trial of NOV03 met both main goal of the study evaluating the eye drop to treat the signs and symptoms of dry eye.